Syncom Formulations (India) credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

1.5	1.5	4.6	72.5	83.2
−111	−111	−85.3	−59.1	12.3
0.00×	0.00×	0.01×	0.25×	0.32×
−0.27×	−0.27×	−0.25×	−0.21×	0.05×
0.02×	0.02×	0.08×	2.44×	4.24×
−1.27×	−1.44×	−1.58×	−1.99×	0.63×
61.38×	61.38×	56.58×	5.57×	4.82×
0.4%	0.4%	1.3%	20.1%	24.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNCOMF₹20.41

Syncom Formulations (India) Limited

· Pharma & Health

₹ CrorePeersHESTERBIO NGLFINE WINDLAS JAGSNPHARMAMRUTANJAN INDOCO SAIPARENTMcap ₹1,919 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	83.2	72.5	4.6	1.5	1.5
Net Debt	12.3	-59.1	-85.3	-111.4	-111.4
Total Debt/Equity	0.32	0.25	0.01	0.00	0.00
Net Debt/Equity	0.05	-0.21	-0.25	-0.27	-0.27
Total Debt/EBITDA	4.24	2.44	0.08	0.02	0.02
Net Debt/EBITDA	0.63	-1.99	-1.58	-1.44	-1.27
Interest Coverage (EBIT/Interest)	4.82	5.57	56.58	61.38	61.38
Total Debt/Total Capital %	24.52	20.10	1.32	0.35	0.35

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.